
Opinion|Videos|January 22, 2025
Long-Term Safety of Second-Line Therapies for PBC
Panelists discuss how long-term safety monitoring for second-line primary biliary cholangitis (PBC) therapies requires systematic assessment of liver function, lipid profiles, and potential drug-specific adverse effects while emerging 5-year safety data for seladelpar continues to demonstrate a favorable risk profile compared with other treatment options.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are the potential risks of long-term therapy with seladelpar, elafibranor, and obeticholic acid, and how can clinicians monitor for and mitigate these risks?
- Discuss the 5-year safety data for seladelpar presented at AASLD 2024.
- Discuss the 5-year safety data for seladelpar presented at AASLD 2024.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
3
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
4
Enlicitide Meaningfully Lowers LDL-C at 24 Weeks in Patients At Risk for ASCVD Events
5

























